Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on averroes trial

Amin, Alpesh, Deitelzweig, Steve, Jing, Yonghua, Makenbaeva, Dinara, Wiederkehr, Daniel, Lin, Jay and Graham, John (2015) Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on averroes trial. Clinical and Applied Thrombosis/Hemostasis, 21 3: 235-240. doi:10.1177/1076029613507335


Author Amin, Alpesh
Deitelzweig, Steve
Jing, Yonghua
Makenbaeva, Dinara
Wiederkehr, Daniel
Lin, Jay
Graham, John
Title Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on averroes trial
Journal name Clinical and Applied Thrombosis/Hemostasis   Check publisher's open access policy
ISSN 1938-2723
1076-0296
Publication date 2015-04-16
Year available 2013
Sub-type Article (original research)
DOI 10.1177/1076029613507335
Open Access Status Not Open Access
Volume 21
Issue 3
Start page 235
End page 240
Total pages 6
Place of publication Thousand Oaks, United States
Publisher SAGE Publications
Language eng
Formatted abstract
Background: The AVERROES trial name is the following: The Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial demonstrated that apixaban reduced the risk of stroke relative to aspirin, without significantly increasing major bleeding risk in patients with atrial fibrillation (AF) considered unsuitable for warfarin therapy. Based on AVERROES trial results, this study compared the medical costs for clinical end points among patients with AF treated with either apixaban or aspirin.

Methods: Medical costs per patient-year for clinical events were determined. Based on clinical event rates for patients in the AVERROES trial, medical costs excluding drug costs were estimated for apixaban- and aspirin-treated patient groups.

Results and Conclusions: Based on AVERROES trial results, among patients with AF unsuitable for warfarin therapy, apixaban use was estimated to be associated with a mean medical cost avoidance of US$735 in a patient-year relative to aspirin. The primary driver was the significant reduction in ischemic stroke rate. The medical cost reduction associated with apixaban use was consistent in sensitivity analyses.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 05 Aug 2016, 19:46:32 EST by System User on behalf of Learning and Research Services (UQ Library)